Maccura Biotechnology Co (SZSE:300463) Total Liabilities : ¥1,588 Mil (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Maccura Biotechnology Co Total Liabilities?

Maccura Biotechnology Co's Total Liabilities for the quarter that ended in Sep. 2024 was ¥1,588 Mil.

Maccura Biotechnology Co's quarterly Total Liabilities increased from Mar. 2024 (¥1,412.02 Mil) to Jun. 2024 (¥1,605.39 Mil) but then declined from Jun. 2024 (¥1,605.39 Mil) to Sep. 2024 (¥1,587.54 Mil).

Maccura Biotechnology Co's annual Total Liabilities declined from Dec. 2021 (¥2,025.17 Mil) to Dec. 2022 (¥1,638.99 Mil) and declined from Dec. 2022 (¥1,638.99 Mil) to Dec. 2023 (¥1,507.79 Mil).

Maccura Biotechnology Co Total Liabilities Historical Data

The historical data trend for Maccura Biotechnology Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maccura Biotechnology Co Total Liabilities Chart

Maccura Biotechnology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2,169.21

2,388.47

2,025.17

1,638.99

1,507.79

Maccura Biotechnology Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															1,665.12	1,507.79	1,412.02	1,605.39	1,587.54

Maccura Biotechnology Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Maccura Biotechnology Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1120.605	+	(175.478	+	211.704
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,508

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	8119.249	-	6611.462
	=	1,508

Maccura Biotechnology Co's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1238.842	+	(150.987	+	197.709
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,588

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	8205.887	-	6618.349
	=	1,588

Maccura Biotechnology Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Maccura Biotechnology Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Maccura Biotechnology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Maccura Biotechnology Co Ltd (SZSE:300463) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Number 8, 2nd Anhe Road, Hi-tech Zone, Chengdu, CHN, 611731

Website

https://www.maccura.com/

Maccura Biotechnology Co Ltd is a China-based in-vitro diagnostic (IVD) integration company engaged in the research and development, production and sales of IVD products. It is also engaged in the sales of foreign brands of in vitro diagnostic products as an agent. The company's developed product and technology development platforms cover clinical biochemistry, chemiluminescent immunoassay, rapid diagnosis, thrombosis, hemostasis, and molecular diagnosis.

Executives

Guo Lei	Director
Wang Deng Ming	Directors, executives
Wang Lin	Supervisors
Wu Ming Jian	Directors, executives
Shi Wei	Directors, executives
Yang Hui	Supervisors
Zhou Yue Guo	Executives
Wang Zhen	Executives
Yu Ping	Executives
Zou Yuan	Supervisors
Xu Sheng Guo	Directors, executives
Liu Qi Lin	Directors, executives
Chu Jian Jun	Executives
Tang Yong	Director
Xu Jin Song	Executives

Maccura Biotechnology Co Headlines

No Headlines